Evidence map›Paper›PMID 37277682›Full record

ArticleMolecular neurobiology2023

IRAK-M Ablation Promotes Status Epilepticus-Induced Neuroinflammation via Activating M1 Microglia and Impairing Excitatory Synaptic Function.

Xiao-Shan Liang, Ting-Lin Qian, Yi-Fan Xiong, Xiao-Tao Liang, Yue-Wen Ding, Xiao-Yu Zhu, Yun-Lv Li, Jie-Li Zhou, Le-Yi Tan, Wei-Peng Li and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Theranostics · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Current neuropharmacology · 2025
    Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Xiao-Shan LiangSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China.
Ting-Lin QianSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China.
Yi-Fan XiongSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China.
Xiao-Tao LiangSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China.
Yue-Wen DingSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China.
Xiao-Yu ZhuSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China.
Yun-Lv LiSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China.
Jie-Li ZhouSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China.
Le-Yi TanThe First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, China.
Wei-Peng LiSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China. wp_lee@smu.edu.cn.
Wei XieSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China. xieweizn@smu.edu.cn.ORCID http://orcid.org/0000-0002-3218-7231
Southern Medical University · CNNanfang Hospital · CNTCM-Intigrated Cancer Center of Southern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epilepsy is one of the most common neurological disorders. The pro-epileptic and antiepileptic roles of microglia have recently garnered significant attention. Interleukin-1 receptor-associated kinase (IRAK)-M, an important kinase in the innate immune response, is mainly expressed in microglia and acts as a negative regulator of the TLR4 signaling pathway that mediates the anti-inflammatory effect. However, whether IRAK-M exerts a protective role in epileptogenesis as well as the molecular and cellular mechanisms underlying these processes are yet to be elucidated. An epilepsy mouse model induced by pilocarpine was used in this study. Real-time quantitative polymerase chain reaction and western blot analysis were used to analyze mRNA and protein expression levels, respectively. Whole-cell voltage-clamp recordings were employed to evaluate the glutamatergic synaptic transmission in hippocampal neurons. Immunofluorescence was utilized to show the glial cell activation and neuronal loss. Furthermore, the proportion of microglia was analyzed using flow cytometry. Seizure dynamics influenced the expression of IRAK-M. Its knockout dramatically exacerbated the seizures and the pathology in epilepsy and increased the N-methyl-d-aspartate receptor (NMDAR) expression, thereby enhancing glutamatergic synaptic transmission in hippocampal CA1 pyramidal neurons in mice. Furthermore, IRAK-M deficiency augmented hippocampal neuronal loss via a possible mechanism of NMDAR-mediated excitotoxicity. IRAK-M deletion promotes microglia toward the M1 phenotype, which resulted in high levels of proinflammatory cytokines and was accompanied by a visible increase in the expressions of key microglial polarization-related proteins, including p-STAT1, TRAF6, and SOCS1. The findings demonstrate that IRAK-M dysfunction contributes to the progression of epilepsy by increasing M1 microglial polarization and glutamatergic synaptic transmission. This is possibly related to NMDARs, particularly Grin2A and Grin2B, which suggests that IRAK-M could serve as a novel therapeutic target for the direct alleviation of epilepsy.

Indexed as

EpilepsyStatus EpilepticusAnimalsInterleukin-1 Receptor-Associated KinasesMiceMicrogliaNeuroinflammatory DiseasesSeizuresInterleukin-1 Receptor-Associated KinasesEpilepsyIRAK-MMicroglial polarizationNMDARPilocarpine

Identifiers

PMID37277682
OpenAlexW4379378790

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.